AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) is a key regulator of cell growth and proliferation.
• Dysregulation of mTOR signaling is implicated in various cancers, including colon cancer.
• AZD8055 is a potent inhibitor targeting both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).

Purpose of the Study:

• To investigate the antitumor efficacy of AZD8055 in colon cancer.
• To elucidate the molecular mechanisms underlying AZD8055's effects on colon cancer cells.
• To evaluate the impact of AZD8055 on tumor growth in a preclinical model.

Main Methods:

• In vitro studies assessed the effects of AZD8055 on colon cancer cell proliferation, apoptosis, and cell cycle progression.
• Western blot analysis was used to examine the phosphorylation status of key proteins in the mTOR signaling pathway, including AKT and S6K1.
• In vivo studies utilized a mouse model of colon cancer to evaluate the antitumor effects of orally administered AZD8055.

Main Results:

• AZD8055 significantly inhibited colon cancer cell proliferation and induced apoptosis (p<0.05).
• Treatment with AZD8055 suppressed the phosphorylation of AKT and S6K1, key downstream targets of mTOR.
• AZD8055 treatment resulted in G0/G1 cell cycle arrest, decreased cyclin D1, increased p27 expression, and reduced levels of phospho-CDK2 and phospho-Rb.
• Oral administration of AZD8055 significantly suppressed tumor growth in mice compared to the control group (p<0.05).

Conclusions:

• AZD8055 exhibits significant antitumor activity against colon cancer by inducing cytotoxicity, apoptosis, and cell cycle arrest.
• The drug effectively inhibits the mTOR signaling pathway and downstream mTOR-dependent cell-cycle progression.
• AZD8055 demonstrates potential as a therapeutic agent for colon cancer treatment.